| Literature DB >> 34711271 |
P Galappatthy1, P Ranasinghe2, C K Liyanage1, M S Wijayabandara1, S Mythily1, R L Jayakody1.
Abstract
BACKGROUND: Identification of internationally comparable indicators of medicines use are important for a country to implement strategies and regulations to improve usage of medicines. Sri Lanka established a new National Medicines Regulatory Authority in 2015 and this survey evaluated the medication use indicators in Sri Lanka, according to the International Network on Rational Use of Drugs (INRUD), prior to its implementation.Entities:
Keywords: International network on rational use of drugs (INRUD); Prescribing indicators; Private sector pharmacies; Rational drug use; Sri Lanka
Mesh:
Substances:
Year: 2021 PMID: 34711271 PMCID: PMC8555184 DOI: 10.1186/s40360-021-00535-5
Source DB: PubMed Journal: BMC Pharmacol Toxicol ISSN: 2050-6511 Impact factor: 2.483
District wise distribution of pharmacies and number of prescriptions collected
| District | Number of prescriptions | Total | % from total planned | ||
|---|---|---|---|---|---|
| Privately owned | State owned (‘Rajya Osusala’ – SPC) | SPC Franchisee | |||
| 1. Ampara | 30 | 30 | NA | 60 | 100 |
| 2. Anuradhapura | 30 | 30 | 29 | 89 | 98.9 |
| 3. Badulla | 30 | 30 | 29 | 89 | 98.9 |
| 4. Batticaloa | 60 | NA | NA | 60 | 100 |
| 5. Colombo | 55 | 60 | 57 | 172 | 95.6 |
| 6. Galle | 60 | 60 | 58 | 178 | 98.9 |
| 7. Gampaha | 60 | 59 | 57 | 176 | 97.8 |
| 8. Hambantota | 29 | 25 | 28 | 82 | 91.1 |
| 9. Jaffna | 30 | 30 | 25 | 85 | 94.4 |
| 10. Kalutara | 59 | 58 | 56 | 173 | 96.1 |
| 11. Kandy | 60 | 30 | 57 | 147 | 98.0 |
| 12. Kegalle | 30 | NA | 28 | 58 | 96.7 |
| 13. Kilinochchi | 58 | NA | NA | 58 | 96.7 |
| 14. Kurunegala | 55 | 29 | 57 | 141 | |
| 15. Mannar | 60 | 0 | 0 | 60 | 100 |
| 16. Mullaitivu | |||||
| 17. Matale | 30 | NA | 28 | 58 | 96.7 |
| 18. Matara | 30 | 30 | 29 | 89 | 98.9 |
| 19. Monaragala | 30 | NA | 28 | 58 | 96.7 |
| 20. Nuwara Eliya | 57 | NA | NA | 57 | 95.0 |
| 21. Polonnaruwa | 30 | 30 | 29 | 89 | 98.9 |
| 22. Puttalam | 30 | NA | 29 | 59 | 98.3 |
| 23. Ratnapura | 57 | 58 | 59 | 174 | 96.7 |
| 24. Trincomalee | 30 | NA | 28 | 58 | 96.7 |
| 25. Vavuniya | 58 | NA | NA | 58 | 96.7 |
| Total | 1058 | 559 | 711 | 2328 | 97.0 |
NA Not available, SPC State Pharmaceuticals Corporation
Top 10 medications prescribed in the different categories of pharmacies
| Medication | Overall | Number of times prescribed (Rank) | ||
|---|---|---|---|---|
| Privately Owned | State owned (‘Rajya Osusala’ – SPC) | SPC Franchisee | ||
| Atorvastatin | 280 (1) 3.9% | 116 (1) 3.8% | 106 (1) 5.3% | 58 (4) 2.4% |
| Losartan | 229 (2) 3.2% | 82 (5) 2.7% | 83 (2) 4.1% | 64 (2) 2.9% |
| Metformin | 219 (3) 3.0% | 95 (3) 3.1% | 67 (4) 3.3% | 57 (5) 2.6% |
| Paracetamol | 193 (4) 2.7% | 99 (2) 3.3% | 28 (9) 1.4% | 66 (1) 3.0% |
| Omeprazole | 186 (5) 2.6% | 85 (4) 2.8% | 39 (8) 1.9% | 62 (3) 2.8% |
| Aspirin | 179 (6) 2.5% | 72 (6) 2.4% | 75 (3) 3.7% | 32 (10) 1.4% |
| Domperidone | 149 (7) 2.0% | NA | 43 (7) 2.1% | 55 (6) 2.5% |
| Clopidogrel | 133 (8) 1.8% | NA | 55 (5) 2.7% | 34 (9) 1.5% |
| Cetirizine | 119 (9) 1.6% | 54 (10) 1.8% | NA | 44 (7) 2.0% |
| Gliclazide | 110 (10) 1.5% | 43 2.4% | 47 (6) 2.3% | NA |
| Amoxycillin | NA | 56 (8) 1.9% | NA | NA |
| Co-amoxyclav | NA | 55 (9) 1.8% | NA | 42 (8) 1.9% |
| Diclofenac sodium | NA | 70 (7) 2.3% | NA | NA |
| Furosemide | NA | NA | 25 (10) 1.2% | NA |
NA - Medications not in the top 10 in given category, SPC State Pharmaceuticals Corporation
WHO/INRUD core drug use indicators overall and in the different categories of pharmacies
| Prescribing Indicator (WHO recommended standard) | Mean ± SD (Median; Range) / Number (%) | |||
|---|---|---|---|---|
| Overall | Privately owned | State owned (‘Rajya Osusala’ – SPC) | SPC Franchisee | |
| Prescribing Indicators | ||||
| 1. Average medicines per encounter (1.6–1.8) | 3.1 ± 1.9 (3; 1–12) | 2.9 ± 1.7 (3; 1–11)a | 3.6 ± 2.2 (3; 1–11)a | 3.1 ± 1.9 (3; 1–12)a |
| 2. Encounters with an antibiotic (%) (20–26.8%) | 553 (23.8) | 287 (27.1)b | 84 (15.0)ab | 182 (25.6)a |
| 3. Encounters with an injection (%) (13.4–24.1%) | 29 (1.2) | 19 (1.8)a | 6 (1.1) | 4 (0.6)a |
| 4. Medicines prescribed in generic name (%) (100%) | 2579 (35.5) | 980 (32.4)b | 819 (40.6)ba | 780 (35.2)a |
| 5. Medicines prescribed from EML (%) (100%) | 4991 (68.8) | 2099 (69.5) | 1368 (67.8) | 1524 (68.7) |
| Patient-care Indicators | ||||
| 1. Medicines actually dispensed (100%) | 6701 (92.4) | 2824 (93.5)a | 1811 (89.8)ab | 2066 (93.2)b |
| 2. Medicines accurately labelled (100%) | 6600 (98.5) | 2758 (97.7) | 1800 (99.4) | 2042 (98.8) |
ab − values in a row with same symbols are significantly different from one another, EML Essential medicines list, SD Standard deviation, SPC State Pharmaceutical Corporation
Index of Rational Drug Prescribing (IRDP) and Index of Rational Patient-Care Drug Use (IRPCDU) across the different categories of pharmacies
| Overall | Privately owned | State owned | SPC Franchisee | |
|---|---|---|---|---|
| Prescribing Indicators | ||||
| 1. Index of non-polypharmacya | 0.55 | 0.59 | 0.47 | 0.55 |
| 2. Index of rational antibiotic useb | 0.98 | 0.86 | 1.00 | 0.91 |
| 3. Index of safe injection usec | 1.00 | 1.00 | 1.00 | 1.00 |
| 4. Index of generic prescribingd | 0.36 | 0.32 | 0.41 | 0.35 |
| 5. Index of EML prescribingd | 0.69 | 0.70 | 0.68 | 0.69 |
| Index of rational drug prescribing (1 + 2 + 3 + 4 + 5) | 3.58 | 3.47 | 3.56 | 3.50 |
| Patient-care Indicators | ||||
| 1. Index of actually dispensed drugsd | 0.92 | 0.94 | 0.90 | 0.93 |
| 2. Index of labeling of drugsd | 0.98 | 0.98 | 0.99 | 0.99 |
| Index of Rational Patient-Care Drug Use (1 + 2) | 1.90 | 1.92 | 1.89 | 1.92 |
Optimal value taken asa1.7, b23.4, c18.75, d100; EML – essential medicines list
WHO/INRUD core drug use indicators in different countries
| Country [Ref] | Type of survey, Year | WHO/INRUD Core Drug use Indicators (WHO recommended value) | ||||||
|---|---|---|---|---|---|---|---|---|
| Prescribing Indictors | Patient Care Indicators | |||||||
| Medicines* (1.6–1.8) | Antibiotics† (20–26.8%) | Injections‡ (13.4–24.1%) | Generic name¥ (100%) | Essential Medicines¶ (100%) | Dispensed# (100%) | Labelled§ (100%) | ||
| Sri Lanka | Present study, 2015 | 3.1 | 23.8% | 1.2% | 35.5% | 68.8% | 92.4% | 98.5% |
| Africa | Region (PC), 2006–2015 | 3.5 | 49.0% | 24.8% | 70.4% | 88.9% | NR | NR |
| Bahrain | PC, 2003 | 2.6 | 26.2% | 8.3% | 14.3% | 99.8% | NR | NR |
| Brazil | National (PC), 2015 | 2.4 | 5.8% | 6.0% | NR | 45.1% | NR | NR |
| China | Provincial (PC), 2009–2010 | 3.2 | 50.9% | 24.4% | NR | 68.3% | NR | NR |
| Jordan | PC, 1999–2000 | 2.3 | 60.9% | 1.2% | 5.1% | 93.0% | 81.8% | 91.4% |
| Pakistan | PC, 2014 | 3.4 | 48.9% | 27.1% | 71.6% | 93.4% | 90.9% | 100% |
| Saudi Arabia | PC, 2010 | 2.4 | 32.2% | 2.0% | 61.2% | 99.2% | 99.6% | 10.0% |
#*Medicines per encounter; †Encounters with an antibiotic; ‡Encounters with an injection; ¥Medicines prescribed in generic name; ¶Medicines prescribed from essential medicines list; #Medicines actually dispensed; §Medicines accurately labelled; NR Not reported; PC Primary Care